Number of the records: 1
Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: Studies in 5/6 nephrectomized rats with aorto-caval fistula
- 1.
SYSNO ASEP 0568956 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: Studies in 5/6 nephrectomized rats with aorto-caval fistula Author(s) Kala, P. (CZ)
Vaňourková, Z. (CZ)
Škaroupková, P. (CZ)
Kompanowska - Jezierska, E. (PL)
Sadowski, J. (PL)
Walkowska, A. (PL)
Veselka, J. (CZ)
Táborský, M. (CZ)
Maxová, H. (CZ)
Vaněčková, Ivana (FGU-C) RID, ORCID
Červenka, L. (CZ)Number of authors 11 Article number 114157 Source Title Biomedicine & Pharmacotherapy. - : Elsevier - ISSN 0753-3322
Roč. 158, February (2023)Number of pages 11 s. Language eng - English Country FR - France Keywords congestive heart failure ; chronic kidney disease ; endothelin system ; endothelin receptor type A ; aorto-caval fistula ; 5/6 nephrectomy OECD category Cardiac and Cardiovascular systems R&D Projects LX22NPO5104 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) Method of publishing Open access Institutional support FGU-C - RVO:67985823 UT WOS 000916209900001 EID SCOPUS 85145296028 DOI 10.1016/j.biopha.2022.114157 Annotation Background: Association of congestive heart failure (CHF) and chronic kidney disease (CKD) worsens the patient's prognosis and results in poor survival rate. The aim of this study was to examine if addition of endothelin type A (ETA) receptor antagonist to the angiotensin-converting enzyme inhibitor (ACEi) will bring additional beneficial effects in experimental rats.Methods: CKD was induced by 5/6 renal mass reduction (5/6 NX) and CHF was elicited by volume overload achieved by creation of aorto-caval fistula (ACF). The follow-up was 24 weeks after the first intervention (5/6 NX). The treatment regimens were initiated 6 weeks after 5/6 NX and 2 weeks after ACF creation.Results: The final survival in untreated group was 15%. The treatment with ETA receptor antagonist alone or ACEi alone and the combined treatment improved the survival rate to 64%, 71% and 75%, respectively, however, the difference between the combination and either single treatment regimen was not significant. The combined treatment exerted best renoprotection, causing additional reduction in albuminuria and reducing renal glomerular and tubulointerstitial injury as compared with ACE inhibition alone.Conclusions: Our results show that treatment with ETA receptor antagonist attenuates the CKD-and CHF-related mortality, and addition of ETA receptor antagonist to the standard blockade of RAS by ACEi exhibits additional renoprotective actions. Workplace Institute of Physiology Contact Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Year of Publishing 2024 Electronic address https://doi.org/10.1016/j.biopha.2022.114157
Number of the records: 1